



**PRAXIS FÜR  
ENDOKRINOLOGIE  
SAARLOUIS**

Prof. Dr. med. Jochen Schneider

## Publikationen

## PUBLICATIONS:

Hansen B., Laczny, C., Aho V.T.E., Frachet-Bour A., Habier J., Ostaszkeski, Michalsen A., Hanslian E., Koppold D.A., Hartmann A., Steckhan N., Mollenhauer B., Schade S., Roomp K., Wilmes P.\*, **Schneider J.G.\*** .(2023). Protocol for a multicentre cross-sectional, longitudinal study in rheumatoid arthritis and Parkinson's disease patients analysing the relation between the gut microbiome, fasting and immune status (ExpoBiome). *BMJ Open*, under review.

Zimmermann S., Costa MBW., Mathew A., Kirshnan S., **Schneider JG.**, Roomp K., Isermann B., Biemann R., Osteocalcin Is Independently Associated with C-Reactive Protein during Lifestyle-Induced Weight Loss in Metabolic Syndrome (2021). *Metabolites* 11(8):526

Hartmann AM., Dell'Oro M., Kessler CS., Schumann D., Steckhan N., Jeitler M., Fischer JM., Spoo M., Kriegel MA., **Schneider JG.**, Häupl T., Kandil FI., Michalsen A., Koppold-Liebscher DA (2021). Efficacy of therapeutic fasting and plant-based diet in patients with rheumatoid arthritis (NutriFast): study protocol for a randomised controlled clinical trial. *BMJ Open* 11(8): e047758.

Biemann R., Buß E., Benndorf D., Lehmann T., Schallert K., Puettker S., Reichl U., Isermann B., **Schneider J.G.**, Saake G., Heyer R. (2021). Fecal metaproteomics reveals reduced gut inflammation and changed microbial metabolism following lifestyle-induced weight loss. *Biomolecules* 11(5): 726.

Badkas A., Nguyen P., Caberlotto L., **Schneider J.G.**, De Landtsheer S., Sauer T. (2021). Degree Adjusted Large-Scale Network Analysis Reveals Novel Putative Metabolic Disease Genes. *Biology* 10(2): 107..

Helmer P., Damm E., Roomp K., **Schneider J.G.** (2021). Association of the Leu33Pro gain of function variant in  $\beta$ 3-integrin with kidney function but not with inflammatory activity in human derived macrophages in diabetes. *Int J Med. Sci.* 18(12): 2661-2665.

Biemann R., Roomp K., Noor F., Krishnan S., Shazad K., Borucki K., Luley K., **Schneider J.G.**, Isermann B. (2020). Gene expression profile of CD14+ blood monocytes following lifestyle-induced weight loss in individuals with metabolic syndrome. *Sci Rep* 10(1): 17855.

Hartl. D., May P., Wei G., Mayhaus M., Glaab E., Antony P., Bobbili D., Koeglsberger S., Pichler S., Spaniol C., Kurz A., Balling R., **Schneider J.G.**, Riemenschneider M. (2020). A rare loss-of-function variant of ADAM17 is associated with familial Alzheimer Disease. *Mol Psychiatry* 25(3): 626-639.

Kraemer M., Krawczyk M., Gruenhage F., Lammert F., **Schneider. J.G.** (2019). Dissection of plasma concentration and enzymatic activity in the association of VAP1 with Chronic Hep C. *J Clin Med* 8(1), 103.

Gonzales-Sanchez C., Fraile J.C., Perez-Turiel J., Damm E., **Schneider J.G.**, Schmitt D., Ihmig F.R. (2019). Capacitive sensing for non-invasive breathing and heart monitoring in non-restrained, non-sedated laboratory mice. *Electronics* 8(1), 34.

Meiser J., Jaeger C., Link A., Hiller K., **Schneider J.G.** (2018). Itaconic acid indicates cellular but not systemic immune system activation. *Oncotarget* 9(63): 32098-32107 .

Atkinson S.J., Gontarczyk A.M., Ellison T.S., Johnson R.T., Kirkup B.M., Alghamadi A., Fowler W.J, Silva B.C., **Schneider J.G.**, Weilbaeher K.N., Mogenson M.M., Bass M.D., Edwards D.R., Robinson S.D. (2018). The  $\beta$ 3-integrin endothelial adhesome regulates microtubule dependent cell migration. *Embo Rep* 19(7):e44578.

May P., Pichler S., Hartl D., Bobbili D., Mayhaus M., Spaniol C., Kurz A., Balling R., **Schneider J.G.**,

Riemenschneider M. (2018). Rare ABCA7 variants in two German families with Alzheimer's disease. *Neurol Genet* 4(2): e224.

Rasche F.M., Rettig R., Frese T., Rasche W.G., Barinka P., Roesl G., Keller F., Lindner T.H., **Schneider J.G.**, Beige J., Ebert T., Schiekofer S. (2018). The pituitary-thyroid axis and prolactin secretion in hemodialysis patients in two endemic regions of Eastern Germany. *Exp Clin Endocrinol Diabetes* 126(6): 349-356.

Rasche M., Joel C., Ebert T., Frese T., Barinka P., Busch V., Rasche W., Lindner T., **Schneider J.G.\***, Schiekofer S.\*, (2018). Dual RAAS blockade with aliskiren in patients with severely impaired chronic kidney disease. *Exp Clin Endocrinol Diabetes* 126(1): 39-52. \* authors contributed equally.

Stathopoulou M.G., Xie T., Ruggiero D., Chatelin J., Rancier M., Weryha G., Kurth M.J., Aldasoro Arguinano A.-A., Gorenjak V., Petrelis A.M., Dagher G., Dedoussis G., Deloukas P., Lamont J., Marc J., Simmaco M., Van Schaik R.H.N., Innocenti F., Merlin J.-L., **Schneider J.**, Alizadeh B.Z., Ciullo M., Seshadri S., Visvikis-Siest S. (2018). A transnational collaborative network dedicated to the study and applications of the vascular endothelial growth factor-A in medical practice: The VEGF Consortium. *Clinical Chemistry and Laboratory Medicine* 56(4): (83-86).

Kaysen A., Heintz-Buschart A., Muller E.E.L., Narayanasamy S., Wampach L., Laczny C., Graf N., Simon A., Franke K., Bittenbring J., Wilmes P., **Schneider J.G.** (2017). Integrated meta-omic analyses of the gastrointestinal tract microbiome in patients undergoing allogeneic hematopoietic stem cell transplantation. *Translational Res*, 186:79-94.e1.

Schiekofer S., Kleber M.E., Maerz W., Rasche F.M., **Schneider J.G.** (2017). The Proline 7 Substitution in the Preproneuropeptide Y is associated with higher hepatic Lipase (HL) activity in vivo. *Int J Endocrinol, ID* 2869090.

Rasche F.M., Stoebe S., Ebert T., Feige S., Hagendorff A., Rasche W.G., Barinka F., Busch V., Sack U., **Schneider J.G.\***, Schiekofer S.\* (2017). Modern peptide biomarkers and echocardiography in cardiac healthy haemodialysis patients. *BMJ Nephrology*, 18(1): 175. \* authors contributed equally.

Rasche F.M., Ebert T., Beckmann J., Busch V., Barinka .F, Rasche W.G., Lindner T.H., **Schneider J.G.\***, Schiekofer S.\* (2017). Influence of Erythropoiesis-Stimulating Agents on HbA1c and Fructosamine in Patients with Haemodialysis. *Exp Clin Endocrinol Diabetes* 125(6): 384-91. \* authors contributed equally.

Delierneux C., Donis N., Servais L., Wéra O., Lecut C., Vandereyken M., Musumeci L., Rahmouni S., **Schneider J.**, Eble J.A., Lancellotti P. Oury C. (2017). Targeting of C-type lectin-like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides. *J Thromb Haemost*, May;15(5):983-99711.

Heintz-Buschart A., May P., Laczny C.C., Lebrun L.A., Bellora C., Krishna A., Wampach L., **Schneider J.G.**, Hogan A., de Beaufort C., Wilmes P. (2016). Integrated multi-omics of the human gut microbiome in a case study of familial type 1 diabetes. *Nat Microbiol*, Oct 10;2: 16180.

Gonzales-Sanchez C., Fraile-Marinero C., Perez-Turiel J., Damm E., **Schneider J.G.**, Zimmermann H., Schmitt D., Ihmig F.R. (2016). Capacitive sensing for non-invasive breathing and heart monitoring in non-restrained, non-sedated laboratory mice. *Sensors*,16(7), E1052.

Biemann R., Penner M., Borucki K., Westphal S., Luley C., Poenicke R., Biemann K., Weikert C., Lux A., Goncharenko N., Marschall H.U., **Schneider J.G.\***, Isermann B\*. (2016). Serum bile acids and GLP-1

decrease following telemetric induced weight loss: results of a randomized controlled trial. *Sci Rep*, 25(6): 30173. \* authors contributed equally.

Su X., Esser A., Amend S., Xiang J., Ross M., Fox, G., Kobayashi T., Steri V., Roomp K., Fontana F., Hurchla M., Knolhoff B., Meyer M., Morgan E., Tomasson J.C., Novack J.S., Zou W., Robinson S.D., Teitelbaum S.L., DeNardo D.G., **Schneider J.G.**, Weilbaecher K.N. (2016). Antagonizing Integrin  $\beta 3$  Increases Immunosuppression in Cancer. *Cancer Res*, 76(12): 3484-95.

Meiser J., Delcambre S., Wegner A., Jäger C., Ghelfi J., d'Herouel A.F., Dong X., Weindl D., Stautner C., Nonnenmacher Y., Michelucci A., Popp O., Giesert F., Schildknecht S., Krämer L., **Schneider J.G.**, Woitalla D., Wurst W., Skupin A., Weisenhorn D.M., Krüger R., Leist M., Hiller K. (2016). Loss of DJ-1 impairs antioxidant response by altered glutamine and serine metabolism. *Neurobiol Dis* 89: 112-25.

Schiekofer S., Zirngibl C., **Schneider J.G.** (2015). Necrotizing sarcoid granulomatosis (NSG): Diagnostic pitfall to watch out for! *J Clin Diag Res*, 9(7).

Ellison T.S., Atkinson S.J., Steri V., Preedy M.E.J., Johnson R.T., Ruhrberg C., Edwards D.R., **Schneider J.G.**, Weilbaecher K.N., Robinson S.D. (2015). Suppressing  $\beta 3$ -integrin triggers a neuropilin-1 dependent change in focal adhesion remodelling that can be targeted to block pathological angiogenesis. *Dis Model Mech* 8(9):1105-19.

Margue C. Reinbach S., Philippidou D., Beaume N., Walters C., **Schneider J.G.**, Nashan D., Behrmann I., Kreis S. (2015). Comparison of a healthy miRNome with melanoma patient miRNomes: are microRNAs suitable serum biomarkers for cancer? *Oncotargets* 6(14): 12110-12127.

Ba Le V\*, **Schneider J.G.\***, Borgeling Y., Berri F., Ducatez M., Guerin J.L., Adrian I., Bordet J.-C., Jandrot-Perrus M., Ludwig S., Riteau B. (2015). Platelet activation and aggregation promote lung inflammation and influenza virus pathogenesis. *AJRCCM*, 191(7): 804-819. \* authors contributed equally.

N'Doye I., Voos H, Darouach M., **Schneider J.G.** (2015). Static output feedback  $H_\infty$  control for a fractional-order glucose-insulin system. *International Journal of Control, Automation, and Systems*, 13(4):1-10.

Elbelt U., Tovato A., Kloth M., Gentz E., Finke R., Spranger J., Galas D., Weber S., Wolc, Koenig K., Arlt W., Buettner R., May P., Allolio B., **Schneider J.G.** (2014). Germline and additional somatic ARMC5 mutations causing familial primary bilateral macronodular adrenal hyperplasia and Cushing's syndrome. *JCEM*, 100(1): E119-28.

**Schneider J.G.\*** Isermann B.H.\*, Kleber M.\*, Winkelmann B., Boehm B., Grammer T., Prueller F., Nawroth P.P., Maerz W. (2014). Intermediate Thrombin Activation is Associated with Reduced Cardiovascular Death. *Int J Cardiol*, 176(1): 139-44. \* authors contributed equally

Leidig-Bruckner G., Finger S., Bruckner T., Scheidt-Nave C., Nawroth P.P., **Schneider J.G.** (2014). Prevalence and predictors of osteoporosis and fractures in patients with type 1 and type 2 diabetes mellitus. *BMC Endocr Disord*, 14(1): 33.

Liivrand M., Heinämiemi M., John E., **Schneider J.G.**, Sauter T., Sinkkonen L. (2014). Combinatorial regulation of lipoprotein lipase by microRNAs during mouse adipogenesis. *RNABiology*, 11(1): 76-91.

Schiekofer S., Bobak I., Kleber M.E., Maerz W., Rudofsky G., Dugi K.A, **Schneider J.G.** (2014). Association between a Gene Variant near Ataxia-Telangiectasia Mutated (ATM) and Coronary Artery

Disease (CAD) in Men. *Diabetes, Vascular Disease Res*, 11(1): 60-3.

Steri V., Ellison T.S., Weilbaecher K.N., **Schneider J.G.**, Edwards D.R., Gontarczyk A., Fruttiger M., Hodivala-Dilke K.M., Robinson S.D. (2014). Acute depletion of endothelial beta3 integrin transiently inhibits tumor growth and angiogenesis. *Circ Res*, 114(1), 79-91.

Roop R.P., Naughton M.J., **Schneider J.G.**, Lammers P.E., Pluard T.J., Johnson F., Eby C.S., Weilbaecher K.N. (2013). Effect of platelet function on circulating tumor cells in patients with metastatic breast cancer. *Breast Cancer Res*, 13(6): 409-15.

Trairatphisan P., Mizera A., Pang J., Tantar A.A., **Schneider J.**, Sauer T. (2013). Recent development and biomedical applications of probabilistic Boolean networks. *Cell Commun Signal* 11(46).  
<https://doi.org/10.1186/1478-811X-11-46>

N'Doye I., Voos H., Darouach M., **Schneider J.G.** (2013).  $H_\infty$  static output feedback control for a fractional-order glucose-insulin system. *FAC Proceedings Volumes*, 46(1), pp. 266-271.

Shiojima I., Schiekofer S., **Schneider J.G.**, Belisle K., Sato K., Andrassy M., Galasso G., Walsh K. (2012). Short-term Akt activation in cardiac muscle cells improves contractile dysfunction in failing hearts. *Am J Pathol*, 181(6): 1969-76.

Su X., Floyd D., Hughes A., Xiang J., **Schneider J.G.**, Hurchla M., Uluckan O., Heller E., Deng H., Zou W., Craft L., Wu K., Hirbe A., Grabowska D., Eagleton M., Townsley S, Steinberg T., Novak D., Conley P., Rogers M, Weilbaecher K. (2012). The ADP receptor P2Y12 regulates osteoclast function and pathologic bone remodeling. *J Clin Invest*, 122(10): 3579-92.

N'Doye I., Voos H., Darouach M., **Schneider J.G.**, Knauf N. (2012). An unknown input fractional-order observer design for fractional-order glucose-insulin system. *IEEE EMBS IECBES*, p. 595-500.

Belisle K., Andrassy M., Boehm B.O., **Schneider J.G.**, Schiekofer S. (2012). Adiponectin fails in improving angiogenesis in a mouse model for type 1 and type 2 diabetes after hind limb ischemia. *ISRN Vascular Medicine, Volume 2012 (2012), Artikel no. 769092*.

Heller E., Hurchla M.A., Xiang J. Chen S., **Schneider J.G.**, Joeng K.S., Vidal M., Goldberg L., Deng H., Hornick M.C., Prior J., Piwnicka-Worms D., Long F., Cagan R., Weilbaecher K.N. (2012). Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment. *Cancer Res*, 72(4), 897-907.

Jurkowski W., Roomp K., Crespo I., **Schneider J.G.**, DelSol A. (2011): PPAR $\gamma$  population shift produces disease-related changes in molecular networks associated with metabolic syndrome. *Cell Death and Differentiation*, Aug 11(2), e192.

Wei X.\*, **Schneider J.G.\***, Chakravarthy M., Semenkovich C.F. (2011). Endothelial lipogenesis maintains vascular function and prevents inflammation by maintaining eNOS integrity. *J Biol Chem* 286(4):2933-45.\*  
*both authors contributed equally.*

**Schneider J.G.\***, Yang, Z.\*, Chakravarthy M., Lodhi I.J., Turk J., Semenkovich C.F. (2010). Macrophage-specific inhibition of De-novo lipogenesis protects against diet-induced atherosclerosis in apoE null mice. *J Biol Chem* 285(30): 23398-409. \* *both authors contributed equally.*

Morgan E.A.\*, **Schneider J.G.\***, Baroni T., Uluckan O, Heller E., Hurchla, M.A., Deng H., Berdy A., Prior J.L.,

Piwnica-Worms D., Teitelbaum S.L., Ross F.P., Weilbaecher K.N. (2010). Dissection of platelet and myeloid cell defects by conditional targeting of the beta3-integrin subunit. *FASEB J* 24(4): 1117-1127. \* authors contributed equally.

**Schneider J.G.**, von Eynatten M., Schiekofer S., Dugi K.A. (2009). Association between Pro12Ala in PPAR $\gamma$ 2 and coronary artery disease in men. *Diabetes Care*, 32(6):e75.

**Schneider J.G.**, Schiekofer S., von Eynatten M., Schlimmer P., Dugi K.A. (2009). The Pro12Ala polymorphism in PPAR $\gamma$ 2 is associated with increased extent of coronary artery disease in men. *Exp Clin Endocrinol Diabetes* 117(9):519-21.

**Schneider J.G.**, Schiekofer S., von Eynatten M., Dugi K.A. (2009). PPAR Variant Influences Angiographic Outcome and 10-Year Cardiovascular Risk in Male Symptomatic Coronary Artery Disease Patients: Response to Regieli et al. *Diabetes Care* 32. 10.2337/dc09-0393.

Morcos M., Schlotterer A., Sayed A.A., Kukudov G., Oikomonou D., Ibrahim Y., Pfisterer F., **Schneider J.**, Bozorgmehr F., Rudofsky Jr. G., Schwenger V., Kientsch-Engels R., Hamann A., Zeier M., Dugi K., Yard B., Humpert P.M., Woude F.V., Nawroth P.P., Bierhaus A. (2008). Rosiglitazone Reduces Angiotensin II and Advanced Glycation End Product-dependent Sustained Nuclear Factor-kappaB Activation in Cultured Human Proximal Tubular Epithelial Cells. *Horm Metab Res*. 40(11):752-9.

Schiekofer S., Belisle K., Galasso G., **Schneider J.G.**, Burster T., Schmitz G., Boehm B.O., Walsh K. (2008). Angiogenic-regulatory network revealed by molecular profiling heart tissue following Akt1 induction in endothelial cells. *Angiogenesis* 11(3):289-99.

Gates A., Bernal-Mizrachi C., Young S., Feng C., **Schneider J.G.**, Coleman T., Townsend R.R., Chakravarthy M.V., Semenkovich C.F. (2007). Respiratory uncoupling in skeletal muscle delays death and diminishes age-related disease. *Cell Metabolism* 6(6): 497-505.

**Schneider J.G.**, Zhu Y., Coleman T., Semenkovich C.F. (2007). Macrophage  $\beta$ 3 Integrin suppresses hyperlipidemia-induced inflammation by modulating TNF $\alpha$  expression. *Atherosclerosis, Thrombosis and Vascular Biology* 27(12): 2699-2706.

Ren J., Proctor B.M., Chen Z., **Schneider J.G.**, Coleman T., Semenkovich C.F., Lupu T., Muslin A.J. (2007). Grb2 is required for atherosclerotic lesion formation. *Atherosclerosis, Thrombosis and Vascular Biology* 27(6):1361-7.

Ren, J., Avery J., Zhao H., **Schneider J.G.**, Ross F.P., Muslin A.J. (2007).  $\beta$ 3 Integrin deficiency promotes cardiac hypertrophy and inflammation. *Journal of Molecular and Cellular Cardiology* 42(2):367-77.

**Schneider J.G.**, Finck B.N., Ren J., Standley K.N., Takagi M., Bernal-Mizrachi C., Muslin A.J., Kastan M.B., Semenkovich C.F. (2006). ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome. *Cell Metabolism* 4(5): 377-391.

Schiekofer S., Franke S., Andrassy M., Chen J., Rudofsky G., **Schneider J.G.**, von Eynatten M., Wendt T., Morcos M., Kientsch-Engel R., Stein G., Schleicher E., Nawroth P.P., Bierhaus A. (2006). Postprandial mononuclear NF-kappaB activation is independent of the AGE-content of a single meal. *Exp. Clin. Endocrinol. Diabetes* 114(4):160-7.

Schiekofer S., Galasso G., Andrassy M., Aprahamian T., **Schneider J.**, Rocnik E. (2006). Glucose control with

insulin results in reduction of NF- $\kappa$ B-binding activity in mononuclear blood cells of patients with recently manifested type 1 diabetes. *Diab Obes Metab* 8(5): 473-482.

Von Eynatten M\*, **Schneider J.G.\***, Humpert P.M., Kreuzer J., Kuecherer H., Katus H.A., Nawroth P.P., Dugi K.A. (2006): Serum adiponectin levels are an independent predictor of the extent of coronary artery disease in men. *JACC* 47(10), 2124-2126. \* both authors contributed equally.

Chakravarthy M.V., Pan Z., Zhu Y., Tordjman K., **Schneider J.G.**, Coleman T., Turk J., Semenkovich C.F. (2005). "New" hepatic fat activates PPAR $\alpha$  to maintain glucose, lipid and cholesterol homeostasis. *Cell Metabolism* 1(5), 309-322.

**Schneider J.G.**, von Eynatten M., Schiekofer S., Nawroth P.P., Dugi K.A. (2005). Association between plasma adiponectin levels with plasma lipases in vivo. *Diabetes Care* 29: 181 (letter: response).

**Schneider J.G.**, von Eynatten M., Schiekofer S., Nawroth P.P., Dugi K.A. (2005). Low plasma adiponectin levels are associated with increased hepatic lipase activity in vivo. *Diabetes Care* 28(9), 2181-2186.

**Schneider J.G.**, von Eynatten M., Dugi K.A. (2005). Atorvastatin increases lipoprotein lipase expression in vitro and activity in vivo. *J Atheroscler Thromb* 12(4), 232-233.

Von Eynatten M., **Schneider J.G.**, Hadziselimovic S., Hamann A., Bierhaus A., Nawroth P.P., Dugi K.A. (2005). Adipocytokines as a novel target for the antiinflammatory effect of atorvastatin in patients with type 2 diabetes. *Diabetes Care* 28(3), 754-55.

Schiekofer S., Galasso G., Andrassy M., Aphramian T., **Schneider J.**, Rocnik E. (2005). Glucose control with insulin results in reduction of NF- $\kappa$ B-binding activity in mononuclear blood cells of patients with recently manifested type 1 diabetes. *Diabetes Obes Metab* 8(5):473-82.

**Schneider J.G.**, von Eynatten M., Schiekofer S., Volkmer J.E., Parhofer K.G., Hamann A., Nawroth P.P., Dugi K.A. (2004). Atorvastatin improves diabetic dyslipoproteinemia and increases lipoprotein lipase activity in vivo. *Atherosclerosis* 175(2), 325-331.

Von Eynatten M, **Schneider J.G.**, Humpert P.M., Rudofsky G., Schmidt N., Barosch P., Hamann A., Morcos M., Kreuzer J., Bierhaus A., Nawroth P.P., Dugi K.A. (2004). Decreased plasma Lipoprotein Lipase in hypoadiponectinemia: an association independent of systemic inflammation and insulin resistance. *Diabetes Care* 27(12):2925-9.

Bierhaus A., Haslbeck K.M., Humpert P.M., Liliensiek B., Dehmer T., Morcos M., Sayed A.A., Andrassy M., Schiekofer S., **Schneider J.G.**, Schulz J.B., Heuss D., Neundorfer B., Dierl S., Huber J., Tritschler H., Schmidt A.M., Schwaninger M., Haering H.U., Schleicher E., Kasper M., Stern D.M., Arnold B., Nawroth P.P. (2004). Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin super family. *J Clin Invest* 114(12):1741-51.

Rudofsky G, Isermann B, Schilling T, Schiekofer S, Andrassy M, **Schneider JG**, Morcos M, Humpert PM, Sayed AA, Witte S, Renn W, Pfohl M, Hamann A, Nosikov V, Schleicher E, Haring HU, Rudofsky G, Ritz E, Nawroth PP, Bierhaus A. (2004). A 63 bp deletion in the promoter of RAGE correlates with a decreased risk for nephropathy in patients with type 2 diabetes. *Exp. Clin Endocrinol Diabetes* 112(3):135-41.

**Schneider J.**, Bundschuh B., Späth C., Landhammer C., Müller H., Götz M., Nawroth P., Heilmann P., Kasperk C. (2004). Discrimination of patients with and without vertebral fractures by ultrasound and DXA

osteodensitometry. *Calcified tissue international* 74(3):246-54.

Tilly N., **Schneider J.G.**, Leidig-Bruckner G., Sommer U., Kasperk C. (2003). Endothelin-1 levels in patients with disorders of the thyroid gland. *Exp Clin Endocrinol Diabetes* 111(2), 80-84.

Schiekofer S, Rudofsky G, Andrassy M, **Schneider J**, Chen J, Isermann B, Kanitz M, Elsenhans S, Heinle H, Balletshofer B, Haring HU, Schleicher E, Nawroth PP, Bierhaus, A. (2003). Glimepiride reduces mononuclear activation of the redox-sensitive transcription factor nuclear factor-kappa B. *Diabetes Obes Metab Jul;5(4):251-26.*

Schiekofer S., Andrassy M., Chen J., Rudofsky G., **Schneider J.**, Wendt T., Stefan N., Humpert P., Stumvoll M., Schleicher E., Haring H.U., Nawroth P.P., Bierhaus A. (2003). Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappaB in PBMCs. *Diabetes* 52 (3):621-33.

**Schneider J.**, Schmidt N., Brandauer K., Schiekofer S., Hamann A., Nawroth P., Dugi K.A. (2002). The Proline 12 Alanine polymorphism in PPAR- $\alpha$  gene is associated with lower lipoprotein lipase activity in vivo. *Diabetes* 51(3), 867-870.

**Schneider J.G.**, Schäfer S., Lettgen B., Keiper T., Dugi K.A. (2002). Severe hepatosplenomegaly in infant siblings with complete lipoprotein lipase deficiency. *The Lancet* 360(9340), 1150.

**Schneider J.G.**, Hierl T., Tilly N., Sommer U., Schiekofer S., Leidig-Bruckner G., Ziegler R., Kasperk Ch. (2002). Elevated plasma Endothelin-1 levels in diabetes. *Am Journal Hypertension* 15(11), 967-972.

**Schneider J.G.**, v.Eynatten M., Dugi K.A., Duex M., Nawroth P.P. (2002). Recurrent deep venous thrombosis due to congenital interruption of the inferior vena cava and heterozygous factor V Leiden mutation. *Journal Int Med* 252(3):276-280.

Keiper T., **Schneider J.G.**, Dugi K.A. (2001). A novel site in lipoprotein lipase (LPL415-438) essential for substrate interaction and dimer stability. *J Lipid Res* 42(8):1180-6.

Dugi K.A., Brandauer K., Schmidt N., Nau B., **Schneider J.G.**, Mentz S., Keiper T., Schaefer J.R., Meissner C., Kather H., Bahner M.L., Fiehn W., Kreuzer J. (2001). Low hepatic lipase activity is a novel risk factor for coronary artery disease. *Circulation* 104(25):3057-62.

Niedermayer I., **Schneider J.**, Feiden W., Kretschmar H.A. (1996). Creutzfeldt-Jakob disease (CJD): A disease related immunohistochemical study. *Neuropathol. Appl Neurobiol.* 22, 51, 54 S118.

#### **Review articles:**

Aho V.T.E., Ostaszewski M., Martin-Gallausiaux C., Laczny C.C., **Schneider J.G.**, Wilmes P. (2022). SnapShot: The Expobiome Map. *Cell Host Microbe* 30(9): 1340-1340.e1.

Wilmes P., Martin-Gallausiaux C., Ostaszewski M., Aho V.T.E., Novikova P.V., Laczny C.C., **Schneider J.G.** (2022). The gut microbiome molecular complex in human health and disease. *Cell Host Microbe* 30(9): 1201-1206.

**Schneider J.G.**, Tozzo E., Chakravarthy M.V. (2022). Editorial: Mitochondrial Biology and Its Role in



Metabolic Diseases. *Front. Endocrinol.* 13:944728.

Noor F, Kaysen A, Wilmes P, Schneider JG. (2018). The gut microbiota and hematopoietic stem cell transplantation: Challenges and potentials. Noor F, Kaysen A, Wilmes P, Schneider JG. *J Innate Immun Oct 4:1-11.*

Schneider J.G., Nadeau J.H. (2015). Turn up the heat: Circulating Serotonin tunes our internal heating system. *Cell Metab, 21(2):156-158.*

Trairatphisan P., Mizera A., Pang J., Tantar A.A., Schneider, J.G., Sauter T. (2013): Recent development and applications of Probabilistic Boolean Networks, *Cell Commun Signal, 11: 46.*

Schneider J.G., Isermann B., Kleber M.E., Maerz. W. (2014). Thrombin: Freund oder Feind – Neues zum „Thrombin- Paradoxon“. *Vasomed 26(6). 312.*

Fritz J.V., Desai, M., Shah P., Schneider J.G., Wilmes P. (2013): From meta-omics to causality: experimental models for human microbiome research. *Microbiome, 1(1):1-14.*

Schneider J.G., Amend S.H., Weilbaecher K.N. (2011). Integrins and bone metastasis: integrating tumor cell and stromal cell interactions. *Bone 48(1):54-65.*

DeSantis P., Rader D.J., Dugi K.A., Schneider J.G. (2008). Endothelial Lipase: A key Player in HDL metabolism modulates inflammation and atherosclerotic risk. *MRMC 8 (6), 619-627.*

Von Eynatten M., Schneider J.G. (2005): The Role of Adiponectin in Atherosclerosis. Do lipids tip the scales? *Future Cardiology 1(6), 775-784.*

Schneider J.G., Semenkovich C.F. (2005): PPAR-: Savior or Savage. *Cell Metabolism 2(6):341-2.*

#### **NCBI profile:**

<https://www.ncbi.nlm.nih.gov/sites/myncbi/1jYSm7G9Kai5d/bibliography/47197833/public/?sort=date&direction=descending>

#### **PATENTS AND MISC. CONTRIBUTIONS:**

Jackson Lab Mouse strain 008819 (C57 Beta3 knockout); (<http://jaxmice.jax.org/strain/008819.html>)

Patents: (WO/2007/059372) Use of chloroquine to treat metabolic syndrome.

#### **MEMBERSHIPS:**

German Association for Internal Medicine (DGIM)

German Association for applied Endocrinology (DGAE)

German Diabetes Association (DDG)

German Atherosclerosis Society (DAG)

Lipid Liga

German –Chinese Association for Medicine

Endocrine Society of the USA

German Association for the treatment of lipid disorders and its complications (DGFF)

#### **SELECTED PEER-REVIEWING ACTIVITIES**

American Journal of Cardiology, Journal of Medical Genetics

Diabetes Care, Diabetes, Obesity and Metabolism, Metabolism

Experimental and Clinical Endocrinology and Diabetes  
The American Journal of Physiology-Endocrinology and Metabolism  
Yonsei Medical Journal, Ageing Research Reviews, Vascular Health and Risk management  
Pharmacological Reports, Nephron, Medical Science Monitor MSM, Mediators of Inflammation, Heart and  
Vessels, Annals of Agricultural&Environmental Sciences; J Medical Genetics, Lipids, BMC Endocrine Disorders

Ad hoc reviewer for the Institute for Quality and Efficiency in Health Care (IQWiG-Germany), the FNRS (Belgium)  
Reviewer to the EU-funded William Harvey International Translational Research Academy (WHRI-ACADEMY)  
Panel review member for the EraCoSysMed consortium.

#### **EDITORIAL BOARD MEMBERSHIPS:**

Dataset Papers in Medicine, ISRN Endocrinology, International Journal of Chronic Diseases, International Journal  
of Pathology and Clinical Research, Heliyon. Journal of Personalized Medicine

#### **FUNDING:**

PMC (Personalized Medicine Consortium) – Luxembourg Pimp Prime funding (50,000.00 Euro)  
“Diabwolt-clinical interventional trial to study mRNA-microRNA gene regulatory networks during weight loss”  
(Eli Lilly, 90,000.00 Euro)  
University of Luxembourg IRP- Dynamic change of host gastrointestinal microbiome and immune status in  
relation to mucosal barrier effects during chemotherapy and immune ablative intervention in humans-  
ImMicroDyn1: 537,000.00 Euro  
HOMfor: The impact of ADP receptor P2Y12 on macrophage and mast cells activation via  $\beta_3$  integrin  
(Itgb3) signalling: 9,000 Euro.  
FNR (Fonds National de la Recherche du Luxembourg) Core grant ITGB3Vascln (2012-2015) - Dissecting cell  
autonomous roles of beta3 integrin: 527,000.00 Euro.  
Marie Curie CIG 303682 (2012-2016): Beta3 integrin conditional deletion in macrophages. 100,000.00  
DFG (German Research Association) SCH682-3-1: Beta3 Integrin in diet induced inflammation (2011-2013),  
133,000.00 Euro.  
IZKB (Interdisciplinary centre for clinical studies) Wuerzburg 2010: Role of beta3 integrin in inflammation  
and atherosclerosis: 25,000.00 Euro  
NIH Ruth L. Kirschstein Service Award Fellowship 2002-2005 “Antiinflammatory Properties  
of Atorvastatin in Patients with Diabetes mellitus” (Pfizer ATV-D-01-006G) 2002: 25,000.00  
Euro  
„Serum-TGF- $\beta$ -level as mechanism of Atorvastatin mediated nephroprotection in diabetes mellitus.“(Pfizer CT  
0981-00SP08), 2002: 25,000.00 Euro  
„In vitro Effects of Rosiglitazone on NF- $\kappa$ B in kidney cells–A potential nephroprotective mechanism?“  
(SmithKline Beecham (BRL 49653/903), 2001:10,000.00 Euro  
Junior research fellowship at the University of Heidelberg: Investigations regarding the structure- function  
relationship and atherogenesis of Endothelial Lipase (EL), 2001-2002: 50,000.00 Euro

#### **ACTIVITIES IN ACADEMIC ADMINISTRATION:**

Since 2012- present	Member of the Ethics Review Panel (ERP) of the University of Luxembourg (UL) (January 2016-December 2018 as Vice-Chair)
Since 2014- present	Member of the Animal Ethics committee at UL and member of the animal welfare body of UL
Since 2016-present	Member of the Comite Nationale D’Ethique de Recherche (CNER)

**OUTREACH ACTIVITIES:**

Articles in public health magazine "Synapse" 2/2014 and 4/2014: "Diagnostic tests in a memory clinic", "Dementia syndromes", and "What represents a memory clinic" respectively.

Lectures in public schools

**SELECTED LICENSING PROJECTS WITH INDUSTRY:**

1. SmithKlineBeecham protocol 496531136: a 26 week randomized double blind multicentre placebo-controlled study to evaluate the efficacy, safety and tolerability of rosiglitazone with concurrent insulin therapy and/or sulphonylurea in type 2 diabetes patients with chronic renal failure.
2. Glaxo PPA30004: a multicentre randomized double blind study on efficacy and tolerability of add-on daily therapy with GI262570 (2,5 mg, 5 mg and 7,5 mg) with insulin therapy in patients with type 2 diabetes (26 weeks, with optional 26 week extension).
3. Novartis DJN B354E00: a multicentre randomized parallel-group, fixed-dose study to prospectively evaluate the efficacy, safety and tolerability of two doses DJN608 plus metformin combination therapy compared to metformin monotherapy in subjects with NIDDM on metformin.
4. Novartis CDJN608 0102: a multicentre open-labelled study to prospectively evaluate the efficacy, safety and tolerability of nateglinide in type 2 diabetes patients with various levels of renal function.
5. Novartis Study XU-SUB: a double-blind, randomized, parallel-group placebo-controlled multicentre study to investigate the effect of fluvastatin on lipoprotein subfractions in hyperlipidemic patients with type 2 diabetes mellitus.
6. GlaxoWellcome AZA30001: a prospective randomized double blind study to compare the efficacy of a titrated dose escalation of telmisartane versus amlodipine in patients with essential hypertension.
7. Zeneca 4522IL/0036: a 24 week randomized multicentre multinational trial to evaluate the efficacy, safety of ZD4522 and fenofibrate, alone and in various combinations in the treatment of type IIb and VI hyperlipidemia associated with type 2 diabetes mellitus.
8. Pharmacia/Upjohn CTN 97-FRAG-032: a double blinded placebo controlled study on the dose-response-relationship of dalteparin (Fragmin) with respect to diminishing of proteinuria in type 2 diabetes patients with diabetic nephropathy.
9. Sanofi: Irbesartan EFC-2481: Study of the effects of irbesartan on microalbuminuria in hypertensive patients with type 2 diabetes mellitus.

**REFERENCES**

Prof. Dr. Rudi [Balling](#)  
Institute of Molecular Psychiatry  
University of Bonn  
Venusberg Campus, Bldg. 76  
Sigmund Freud Str. 25  
D-53127 Bonn  
Tel: +49-15114729676  
Email: [rballing@uni-bonn.de](mailto:rballing@uni-bonn.de)

Prof. Dr. med. Michael Menger  
Universität des Saarlandes  
Dekan, Medizinische Fakultät  
Gebäude 15 Kirrberger Straße 100  
66421 Homburg  
T: +49 6841 16-26005  
Email: [michael.menger@uks.eu](mailto:michael.menger@uks.eu)

Prof. Dr. M. Fassnacht  
Leiter des Lehrstuhls Endokrinologie & Diabetologie  
Leiter Bereich Forschung des Zentrallabors  
Universitätsklinikum Würzburg  
Oberdürrbacherstr. 6  
97080 Würzburg  
Tel 0931-201-39021  
Email: [Fassnacht\\_m@ukw.de](mailto:Fassnacht_m@ukw.de)

Katherine Weilbaeher, MD  
Oliver M. Langenberg Distinguished Professor of the Science and Practice of Medicine  
Professor of Medicine and Cellular Biology and Physiology  
Department of Medicine  
Division of Molecular Oncology  
Washington University School of Medicine  
+314-454-8858  
Email: [kweilbae@wustl.edu](mailto:kweilbae@wustl.edu)

Prof. Dr. med. Christoph Schindler  
Head CRC Core Facility, Clinical Trial Unit  
Clinical Research Center  
Medizinische Hochschule Hannover (MHH)  
OE 8660, Feodor-Lynen-Strasse 15, 30625 Hannover, Deutschland  
Tel.: +49 511 5350-8300, Fax: +49 511 5350-8350  
Email: [schindler.christoph@mh-hannover.de](mailto:schindler.christoph@mh-hannover.de)